cyrilzakka/clinical-trials huggingface dataset:
Comparing Effects of Kinesio and Dynamic Tapings in Postpartum Women With Pelvic Girdle Pain

About 45% of pregnant women and 25% of women postpartum suffer from Pelvic girdle pain. Pain is often reported to be localized between costal margin and gluteal fold with or without radiation to lower limb or symphysis pubic. Kinesio taping (KT) is the application of an elastic tape, for treating musculoskeletal conditions through enhancing muscle strength, relieving spasms, pain and edema, improving blood circulation and lymph reflux, as well as stabilizing joints. However, with limited evidence and a lack of well-designed study, the effects of KT in postpartum women with PGP remains unclear. Compared with KT, the dynamic taping(DT) is recently developed and has stronger elastic resistance and recoil. The DT may have better effects than the KT, although this notion has not been examined. In this study, we make a hypothesis that PGP women in the DT group would have better improvements on pain, disability, quality of life, and PFM functions than that in the KT group and control group.

The main purpose for this study are to investigate the effects of KT and DT on pain, disability, physical functions, and quality of life, as well as PFM functions in postpartum women with PGP. 60 postpartum women with PGP will be randomized into one of the three groups:(1) kinesio taping group,(2) dynamic taping group (3)control group, and receive 4 weeks intervention. All participants will receive 3 assessments at the baseline, immediately after first taping session, and after 4-week interventions. The outcome measures will include Visual Analog Scale measures of pain intensity, Pelvic Girdle Questionnaire/ Oswestry Disability Index/ Patient specific functional scale measures and Global rating of change score. for disability. The quality of life will be measured by 36-item Short-Form Survey， The Physical functions include Active Straight Leg Raise Fatigue task , Time up and go test,10-meter walk test. The PFM functions will be measured by Modified Oxford grading scale and Perineometer. It is expected that PGP women in both the KT group and DT group will have more improvements than the control group. But the DT group will have even more improvements than the KT groups.

Eligibility Criteria:
Inclusion Criteria:

1. Age: \> 20 year
2. Postpartum:≥ 3 months
3. Pain onset during pregnancy
4. Pain location is located between costal margin and gluteal fold with or without radiation to lower limb or symphysis pubic
5. Clinical screening test for pelvic pain :

Active Straight Leg Raising : positive

* 2 (+) posterior pelvic pain provocation tests (+ symphysis ≥ 1)

Exclusion Criteria:

1. BMI ≥ 30
2. lumbar or pelvic surgery
3. History of fracture
4. Radiculopathy or myopathy
5. Gynaecological disorders
6. Serious cardiovascular disease
7. Tumors
8. Diagnosed psychiatric disease
9. Ongoing pregnancy
10. Allergy to acrylic
Usage of Orange Peel Extract in Management of Epistaxis

Efficacy of orange peel extract in treatment of epistaxis in children

Formulation of orange peel extract into gel substance and usage of it in local treatment of epistaxis

Eligibility Criteria:
Inclusion Criteria:

* children with anterior epistaxis from little's area

Exclusion Criteria:

* patient with nasal polyp.
* patients with hematological abnormalities.
* patients with general diseases affecting coagulation system.
Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Panobinostat is a potent oral histone deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the US Food and Drug Administration for use in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma (MM) who have received ≥ 2 prior regimens, including bortezomib and an immunomodulatory drug.

A GEP-based histone acetylation score allowing identification of MM patients with a poor prognosis and who could benefit from HDACi treatment was recently reported(Moreaux et al. BJC. 2013).

Our hypothesis is that the histone acetylation score could be promising to identify MM patients who could benefit from treatment with HDACi and the development of personalized treatment.


Eligibility Criteria:
Inclusion Criteria:

* Relapsed/refractory multiple myeloma
* Aged 18 years or more with no upper age limit
* Have signed an informed consent

Exclusion Criteria:

NA
Sleep Quality, Stress, Depression, Blood Pressure Responses to Diaphragmatic Respiratory Exercise in Systemic Sclerosis

systemic sclerosis women usually report problems such as stress/depression, fatigue, not deep sleep. complementary therapies may improve the reported problems in those patients

the assignment of females with systemic sclerosis (n= forty females) to two equal groups. the group will contain 20 females. the first group will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females). the females in the second group will be waiting-list control females.

Eligibility Criteria:
Inclusion Criteria:

* systemic sclerosis women (40 females)

Exclusion Criteria:

* obesity
* thoracic diseases
* heart disease
* females with mental diseases
Clinical Trial on the Use of 25-OH -D Vitamin in Haemodialysis Patients

Multicentric randomized Italian clinical trial, open label, not for profit. To evaluate the efficacy of 25-OH-D vitamin in terms of myocardial infarction, stroke, sudden death, death for other causes in chronic haemodialysis patients. Two arms of treatment: 25-OH-D vitamin per os versus no treatment.


Eligibility Criteria:
Inclusion Criteria:

* age \>= 18 years
* hematic PTH level twofold-ninefold the upper limit
* hematic level of 25-OH-D vitamin \< 30 ng/ml

Exclusion Criteria:

* renal transplant or peritoneal dialysis less than 3 years ago
* pregnancy
* breastfeeding
Erector Spinae Plane Block For Lumbar Disc Hernia Repair

Pain management after lomber disc hernia repair surgery is a challenging issue for anesthetists. Erector Spinae plane block is a novel analgesic technique which could be used for this purpose. Primary aim of this double blinded randomized controlled study is to compare the analgesic efficacy of this new block technique with control group in this group of patients.


Eligibility Criteria:
Inclusion Criteria:

* ASA I-II
* Age 18-65 years
* Undergoing elective lomber disc hernia

Exclusion Criteria:

* obesity
* ASA III - IV
* infection of the skin at the site of needle puncture area
* patients with known allergies to any of the study drugs
* coagulopathy
A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers

The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.

The primary purpose of the study is to determine whether a device called the Breast Cancer Locator (BCL) accurately identifies the location of cancer in the breast. The Breast Cancer Locator is a plastic bra-like form that gives the surgeon information about the location of the cancer in the breast. The location information is derived from an MRI which is obtained with the patient lying flat on their back (just as they are on an operating room table). The BCL is then custom-made for the patient using 3D printing technology.

The surgeon can feel the cancer, and the surgeon will remove the cancer by feeling the edges of it as the surgeon would normally. Since the cancer can be felt, the surgeon does not need an image guidance system such as the BCL to locate the cancer in the breast. Other women may have breast cancers that cannot be felt, but are only identified by mammography or MRI. If the BCL proves to accurately localize breast cancer, it may be a useful guide for the surgeon for these other women.

Additionally, the investigators want to determine whether this technology can be successfully employed at multiple sites and what, if any, complications occur during surgery as a result of using this device. The BCL has been used in 19 patients at Dartmouth with no complications.

Eligibility Criteria:
Inclusion Criteria:

1. Age \> 18 years.
2. Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
3. Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
4. Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
5. The cancer enhances on prone breast MRI imaging
6. The cancer is visible on mammography.

Exclusion Criteria:

1. Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
2. Severe claustrophobia.
3. Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine \> 2.0).
4. History of median sternotomy.
5. Pregnancy. Patient attestation that they are not pregnant will be acceptable.
6. Patients receiving neoadjuvant chemotherapy.
Validity and Reliability of ICIQ-FLUTS LF in Thai Version and Correlation With IPSS

The investigators recruited participants, who were female with LUTS 50 participants for known group validity and 80 normal control females to evaluate for construct validity and test for reliability by statistical analysis.

50 females with LUTS will completed the ICIQ-FLUTS and IPSS and then again at 2 weeks apart to test for convergent validity and test-retest validity.

The normal control group 80 women will completed ICIQ-FLUTS LF for test of construct validity.

Eligibility Criteria:
Inclusion Criteria:

* age at or over 18 years old
* can read and understand Thai language
* have lower urinary tract symptoms

Exclusion Criteria:

* those who have a diagnosis of calculi, urinary tract cancer
Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity

Patients with coronary artery disease (CAD) are often treated with dual antiplatelet therapy (DAT), including aspirin and clopidogrel, to prevent from recurrent atherothrombotic events.

Levels of platelet reactivity in patients on DAT can be influenced by concomitant treatment with medications that inhibit the CYP3A4 system involved in the activation of clopidogrel.

Atorvastatin and simvastatin are metabolized by CYP3A4 \[Clin pharmacokinetic 2002; 41: 343-70\], whereas the cytochrome P450 mediated metabolism of rosuvastatin appears to be minimal and principally mediated by the 2C9 isoenzyme, with little involvement of CYP3A4 \[Clin Ther 2003; 25: 2822-5.\].

Previous studies comparing atorvastatin versus rosuvastatin by means of ex vivo platelet function tests have yielded conflicting results.

At least 1 month after starting DAT (clopidogrel 75 mg and aspirin 100 mg), patients will receive randomly atorvastatin (20 mg day, N=50) or rosuvastatin (10 mg bid, N=50) for 30 days (until T-1).

At this time-point, there will be a wash-out period of 15 days after the first treatment with atorvastatin or rosuvastatin in order to avoid any carry-over effect.

Afterwards, a cross-over will be performed, and patients will be switched to the other drug which will be continued for further 30 days (until T-2).

Eligibility Criteria:
Inclusion Criteria:

* Angiographically-proven coronary artery disease
* Class I indication to DAT because of recent (\<12 months) percutaneous coronary intervention and/or recent acute coronary syndrome (\<12 months)
* Stable clinical conditions
* Able to understand and willing to sign the informed CF

Exclusion Criteria:

* Use of other drug interfering with CYP activity such as proton pump inhibitors
* Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before CT
Pancreas Cancer Surveillance Using an Abbreviated MRI

This study aims to establish a prospective cohort of developing pancreas cancer and surveillance MRI protocol. With the focused surveillance protocol, we perform surveillance for pancreas cancer for five years to estimate the risk of pancreas cancer and the clinical feasibility of the surveillance MRI.


Eligibility Criteria:
Inclusion Criteria:

* On follow-up due to first degree-family history of PAC
* Or on follow-up for BD-IPMN (\>= 2 cm) or main-duct type IPMN (\> 5 mm)
* And signed informed consent

Exclusion Criteria:

* Contra-indication of performing MRI
* Not satisfying the selection criteria.
* Previously diagnosed with pancreatic malignancy
* Pregnancy or planning pregnancy
Assesment of Multiomics Profiles in Health and Disease.

This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population and will evaluate its correlation with the disease phenotype.

This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population. Initially, there will be 1000 healthy volunteers, with the planned expansion to 10.000 participants (healthy volunteers and patients with different types of disease). Formation of the reference database of healthy volunteers and their parameters will allow a correct interpretation of the potential pathological findings in patients. It is very important to obtain healthy controls from the region of the Czech Republic, Central Europe respectively; since it is not possible to reliably compere ethnically and geographically diverse populations, which have generated in a different context and where the diseases manifest with other etiology ad phenotype. Although, in the limited measure, the similar molecular data exist in foreign databases, these are not compiled from the inhabitants of the Czech Republic, Central Europe not even from Slavic population. Study participants may volunteer for archiving of remaining biological materials for future studies.

Eligibility Criteria:
Inclusion Criteria:

* age 18 - 68 years
* (for the first 1100 subjects):
* healthy volunteers without genetically dependent disease and without such a disease in a family
* healthy volunteer without the preliminary evidence of civilizational diseases such as hypertension, diabetes, autoimmune and tumor diseases or acute infectional diseases; clinically manifesting cardiovascular or pulmonary disability.
* subject without permanent of long-term medication in the time of biological sampling.

Exclusion Criteria:

* not complying with inclusion criteria
Impact of Vitamin D on Diabetic Kidney Disease in African Americans

This purpose of this project is to evaluate the effectiveness of vitamin D supplementation over 12 months in vitamin D deficient African American adults with type 2 diabetes.

Diabetic kidney disease is increasing in prevalence and is associated with significant morbidity and mortality. Health disparities exist in the progression of diabetic kidney disease, with minorities being more affected even when adjusting for treatment, glycemic and hypertensive control, and medical coverage. Secondary prevention of the progression of diabetic kidney disease is hindered by a lack of easily modifiable risk factors. Based on animal and observational human studies, vitamin D deficiency is potentially a novel, modifiable risk factor that may interrupt or delay the progression of diabetic kidney disease through direct effects as well as by helping to ameliorate kidney disease risk factors, such as hyperglycemia, hypertension and inflammation. In addition, based on minorities having a higher prevalence of vitamin D deficiency, it may also potentially impact the differential progression of diabetic kidney disease in minorities. However, clinical trials evaluating the impact of vitamin D supplementation on diabetic kidney disease are lacking. Thus, this pilot study funded as an R03 through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has the following specific aims: (1): To evaluate the impact of vitamin D supplementation (vitamin D3 at 400 IU/d versus 4000 IU/d) on the proportion of individuals with progression of albuminuria over 12 months in a sample of African American participants with vitamin D deficiency in a randomized controlled trial. (2): To identify whether kidney disease risk factors such as blood pressure and glycemic control mediate the impact of vitamin D supplementation on the progression of albuminuria over 12 months in a sample of African American participants with vitamin D deficiency in a randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* African American race
* Diagnosis of Type 2 Diabetes
* Stage 1 or 2 Kidney Disease with detectable microalbuminuria \>4.0 (mg/g) 25(OH)D level \<20 ng/ml

Exclusion Criteria:

* Type 1 diabetes

  --\> Stage 3 Kidney Disease, or history of dialysis, kidney transplantation or nephrolithiasis
* Unable to provide informed consent or contact information
* Pre-existing calcium or parathyroid condition, including serum calcium \>10.2 mg/dL
* Sarcoidosis, active tuberculosis, or malignancy
* Known hypersensitivity to vitamin D or any of its analogues and derivatives
* Current pregnancy or planning to become pregnant in next 15 months
Echinaforce COVID-19 Shedding Study

Respiratory viruses pose a permanent threat to humans and society as demonstrated by the current Covid-19 pandemic. Novel drugs and vaccines provide a means for controlling illness. Infections and symptomatic presentation of illness may be reduced, but it remains to be determined to which extent viral shedding and transmission (e.g. by silent transmitters) can be controlled. Lack of such activity may result in continuing viral spread by assumed healthy but asymptomatic spreaders. Echinacea is an established and readily-accessible product with demonstrated in vitro antiviral activity (including coronaviruses). This study aims to estimate the potential of different Echinacea formulations (head-to-head) to reduce concentration infectivity and shedding of SARS-CoV-2 under in vivo conditions.


Eligibility Criteria:
Inclusion Criteria:

* Age 12 - 75 years.
* Written informed consent.
* Ability and willingness to give oropharyngeal swab samples.
* Positive pre-screening SARS-CoV-2 RT-PCR virus test with an above threshold viral load as per qPCR (Cq ≤ 27).

Exclusion Criteria:

* ≥76 years
* \<12 years.
* Participation in another clinical study in the past 30 days or planned during study conduct.
* Severe COVID19
* Intake of antimicrobial, antiviral, immune suppressive substances.
* Surgical intervention in the 3 months prior enrolment
* Known diabetes mellitus.
* Known and medicated atopy or asthma.
* Cystic Fibrosis, bronchopulmonary dysfunction, COPD.
* Known immune system disorders and degenerative disorders (autoimmune disorders, AIDS, leukemia, lymphoma, myeloma).
* Known metabolic or resorption disorders.
* Known liver or kidney illnesses (chronic hepatitis, liver cirrhosis, chronic kidney insufficiency).
* Serious health conditions (limited general condition, auto-immune diseases, tumorous diseases, neurological disorders or serious Covid-19)
* Known allergies to plants of the compositae family (e.g. chamomile or dandelion) or to one of the compounds in the investigational product
* Known pregnancy.
The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies

The purpose of this study is to compare the efficacy of a low-volume bowel preparation versus a high-volume bowel preparation for bowel cleansing on hospitalized patients undergoing colonoscopies.


Eligibility Criteria:
Inclusion criteria:

1. Inpatient colonoscopy
2. Age 18 years and older
3. Able to give consent
4. Split dose colonoscopies for all patients

Exclusion criteria:

1. Unable to give consent
2. Pregnant or lactating women
3. Renal impairment (GFR \<30)
4. Ileus
5. Ascites
6. Toxic megacolon
7. Gastrointestinal obstruction
8. Allergy to study drugs
9. Toxic colitis
10. Not able to split the dose of bowel preparations to be used
11. Contraindication to bowel preparation
12. Risk for aspiration
13. Risk of severe cardiac arrhythmias
Open-label Extension to Protocol 1042-0500

To allow open-label extension to patients who have completed Protocol 1042-0500

Patient should have completed all scheduled clinical study visits in the double blind, controlled trial (Protocol 1042-0500) and have been deemed eligible (had a response to treatment) by the Investigator. Male or female, with a diagnosis of IS with a video EEG (vEEG) recording confirming the diagnosis.

There will be a total of 14 visits over 99(+or-1)week. A 24-hr vEEG is only required if the subject has been spasm-free for more than 24-hrs.

Eligibility Criteria:
Inclusion Criteria:

* Have completed all scheduled clinical study visits in the previous Protocol 1042 0500 and have been deemed eligible (no SAEs thought to be drug related and had a response to treatment) by the Investigator.
* Be diagnosed with IS regardless of etiology. Diagnostic Criteria: Seizures consisting of single or repetitive short muscular contractions leading to flexion or extension. Spasms may be characterized as tonic or myoclonic contractions, may occur singly or in clusters, and typically occur bilaterally and symmetrically. The EEG pattern must be consistent with the diagnosis of IS (hypsarrhythmia, modified hypsarrhythmia, multifocal spike wave discharges, etc).
* Have a 24 hour vEEG recording confirming the diagnosis of IS.
* Have had a magnetic resonance imaging (MRI) performed to determine any possible causes of IS.
* Have been previously treated with 3 AEDs or fewer.
* Have a parent/guardian who is properly informed of the nature and potential risks and benefits of the clinical study, is willing and capable of complying with all clinical study procedures, and has given informed consent in writing prior to entering the clinical study.

Exclusion Criteria:

* Current treatment with more than 2 concomitant AEDs.
* Have an active CNS infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive (with the exception of tuberous sclerosis) as evaluated by brain MRI.
* Have any disease or condition (medical or surgical) at Screening that might compromise the hematologic, cardiovascular, pulmonary, renal, GI, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or would place the subject at increased risk.
* Aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin greater than 4 times the upper limit of laboratory normal or any clinical laboratory value deemed clinically significant by the Investigator.
* History of recurrent status epilepticus.
* Have been exposed to any other investigational drug within 30 days prior to enrollment.